He has pioneered the use of stem cells and biomaterials to treat a range of life threatening diseases
Cryoport announced the appointment of Robert Hariri to its Board of Directors. Hariri is the Chairman, Founder and Chief Scientific Officer of Celgene Cellular Therapeutics, a human cellular therapeutics companies and wholly-owned subsidiary of Celgene Corporation. He has pioneered the use of stem cells and biomaterials to treat a range of life threatening diseases and has made transformative contributions in the field of tissue engineering.
Hariri is a visionary scientist, surgeon, aviator and entrepreneur. He has over 100 issued and pending patents; authored over 100 published chapters, articles and abstracts; and is most recognised for his discovery of pluripotent stem cells from the placenta and as a member of the team which discovered the physiological activities of TNF (tumour necrosis factor).
Hariri stated, “As an established investor in Cryoport’s common stock, I have a great deal of confidence in the need and demand for Cryoport’s cold chain and logistical solutions in the life sciences market, which is expected to increase substantially as cellular therapies such as stem cells, immunotherapies and, especially, CAR-T cell therapies come to commercialisation. These advanced therapies require rigid and well-designed enhanced cold chain management solutions to ensure effective patient treatment, as temperature excursion will affect efficacy. To effectively bring these therapies through clinical trials and commercialisation, after receiving FDA approval, the use of advanced cold-chain solutions, such as Cryoport’s, is crucial. The cellular therapies market, on a broad scale, is greatly enhanced by the presence and use of Cryoport’s technologies.”